ALCAM, activated leukocyte cell adhesion molecule, is a type I membrane glycoprotein and a member of the immunoglobulin supergene family. It is also known as CD166, MEMD, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat. ALCAM is expressed on thymic epithelial cells, activated B and T cells, and monocytes. ALCAM can bind itself homotypically and is also capable of binding CD6, NgCAM, and other, as of yet, unidentified brain proteins. The ALCAM/CD6 interaction may be involved in T cell development and T cell regulation. Additionally, ALCAM/CD6 and ALCAM/NgCAM interactions may play roles in the nervous system. ALCAM has also been observed to be upregulated on highly metastasizing melanoma cell lines and may play a role in tumor migration. ALCAM is a 583 amino acid (aa) protein consisting of a 27 aa signal peptide, a 500 aa extracellular domain, a 24 aa transmembrane domain and a 32 aa cytoplasmic domain. The extracellular domain of ALCAM contains 5 Ig-like domains.
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Western Blot, Adhesion Blockade
Cited:
Immunohistochemistry, Immunohistochemistry-Frozen, Western Blot, Immunocytochemistry
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Loading...
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human ALCAM/CD166
Trp28-Ala526
Accession # AAB59499
Trp28-Ala526
Accession # AAB59499
Specificity
Detects human ALCAM/CD166 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse ALCAM/CD166 is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human ALCAM/CD166 Antibody
Detection of Human ALCAM/CD166 by Western Blot
ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human ALCAM/CD166 by Western Blot
ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human ALCAM/CD166 by Western Blot
ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human ALCAM/CD166 by Western Blot
ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human ALCAM/CD166 Antibody
Application
Recommended Usage
Adhesion Blockade
The adhesion of HuT 78 human cutaneous T cell lymphoma cells (5 x 104 cells/well) to immobilized Recombinant Human CD6 Fc Chimera (Catalog # 627-CD, 10 µg/mL, 100 µL/well) was maximally inhibited (80-100%) by 25 µg/mL of the antibody.
Western Blot
0.1 µg/mL
Sample: Recombinant Human ALCAM/CD166 Fc Chimera (Catalog # 656-AL)
Sample: Recombinant Human ALCAM/CD166 Fc Chimera (Catalog # 656-AL)
Reviewed Applications
Read 1 review rated 5 using AF656 in the following applications:
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: ALCAM/CD166
References
- Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
- Aruffo, A. et al. (1997) Immunol. Today 18:498.
- Degen, W.G. et al. (1998) Am. J. Pathol. 152:805.
Long Name
Activated Leukocyte Cell Adhesion Molecule
Alternate Names
CD166
Gene Symbol
ALCAM
UniProt
Additional ALCAM/CD166 Products
Product Documents for Human ALCAM/CD166 Antibody
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Human ALCAM/CD166 Antibody
For research use only
Related Research Areas
Citations for Human ALCAM/CD166 Antibody
Powered by Bioz
Customer Reviews for Human ALCAM/CD166 Antibody (1)
5 out of 5
1 Customer Rating
Have you used Human ALCAM/CD166 Antibody?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Customer Images
Showing
1
-
1 of
1 review
Showing All
Filter By:
-
Application: Immunohistochemistry-FrozenSample Tested: Embryonic spinal cordSpecies: MouseVerified Customer | Posted 05/08/2019E12.5 CD1 Mouse Spinal cord. In blue, the floor plate is labelled using Alcam/CD166 antibody.
There are no reviews that match your criteria.
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Cellular Response to Hypoxia Protocols
- R&D Systems Quality Control Western Blot Protocol
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars
